| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize tumor necrosis factor receptor superfamily, member 9. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG2, λ |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; ELISA; IHC; FC; IP; IF; FuncS |
| Application Notes | The antibody is recommended for detection of TNFRSF9 by ELISA, IHC, FC, IP, IF, FuncS assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TNFRSF9 |
| Alternative Name | TNFRSF9; tumor necrosis factor receptor superfamily; member 9; ILA; 4-1BB; CD137; CDw137; tumor necrosis factor receptor superfamily member 9; CD137 antigen; T cell antigen ILA; T-cell antigen ILA; 4-1BB ligand receptor; homolog of mouse 4-1BB; receptor protein 4-1BB; T-cell antigen 4-1BB homolog; induced by lymphocyte activation (ILA); interleukin-activated receptor; homolog of mouse Ly63 |
| Gene ID | 3604 |
| UniProt | Q07011 |
| Research Area | Cell Biology |
| Related Disease | B cell lymphoma, Non-Hodgkin's lymphoma, Solid tumours |
Figure 1 Anti-TNFRSF9 Monoclonal Antibody (V3S-0522-YC1483) in ELISA
ELISA analysis of V3S-0522-YC1483 was performed by coating with Recombinant Human TNFRSF9 Protein. Then blocked with BSA, and incubated with Anti-Human TNFRSF9 Antibody (V3S-0522-YC1483). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 1 Anti-TNFRSF9 Monoclonal Antibody (V3S-0522-YC1483) in ELISA
Figure 2 Anti-TNFRSF9 Monoclonal Antibody (V3S-0522-YC1483) in WB
Western blot analysis of V3S-0522-YC1483 was performed by loading Recombinant Human TNFRSF9 Protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC1483 and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)
Figure 2 Anti-TNFRSF9 Monoclonal Antibody (V3S-0522-YC1483) in WB
